Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes

Diabetes Care ◽

10.2337/dc15-0258 ◽

2015 ◽

pp. dc150258 ◽

Cited By ~ 19

Author(s):

Angus G. Jones ◽

Timothy J. McDonald ◽

Beverley M. Shields ◽

Anita V. Hill ◽

Christopher J. Hyde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Glycemic Response ◽

Agonist Therapy ◽

Β Cell

Download Full-text

Review for "Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial"

10.1111/dom.14068/v1/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Agonist Therapy ◽

Β Cell

Download Full-text

Review for "Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial"

10.1111/dom.14068/v2/review1 ◽

2020 ◽

Author(s):

Yoshiyuki Hamamoto

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Agonist Therapy ◽

Β Cell

Download Full-text

Author response for "Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial"

10.1111/dom.14068/v2/response1 ◽

2020 ◽

Author(s):

Stefano Del Prato ◽

Juan Pablo Frias ◽

Lawrence Blonde ◽

Vanita R. Aroda ◽

Niam Shehadeh ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Author Response ◽

Agonist Therapy ◽

Β Cell

Download Full-text

Decision letter for "Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial"

10.1111/dom.14068/v1/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Agonist Therapy ◽

Β Cell

Download Full-text

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14068 ◽

2020 ◽

Vol 22 (9) ◽

pp. 1567-1576 ◽

Cited By ~ 1

Author(s):

Stefano Del Prato ◽

Juan Pablo Frias ◽

Lawrence Blonde ◽

Vanita R. Aroda ◽

Niam Shehadeh ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Agonist Therapy ◽

Β Cell ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Decision letter for "Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial"

10.1111/dom.14068/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Agonist Therapy ◽

Β Cell

Download Full-text

Review for "Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial"

10.1111/dom.14068/v1/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Agonist Therapy ◽

Β Cell

Download Full-text

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

Diabetes Metabolic Syndrome and Obesity Targets and Therapy ◽

10.2147/dmso.s48837 ◽

2013 ◽

pp. 435 ◽

Cited By ~ 6

Author(s):

Mark Stolar ◽

Steve Chen ◽

Michael Grimm

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Extended Release ◽

Agonist Therapy

Download Full-text

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany

PLoS ONE ◽

10.1371/journal.pone.0152281 ◽

2016 ◽

Vol 11 (3) ◽

pp. e0152281 ◽

Cited By ~ 4

Author(s):

Qing Qiao ◽

Susan Grandy ◽

Josh Hiller ◽

Karel Kostev

Keyword(s):

Type 2 Diabetes ◽

Primary Care ◽

Receptor Agonist ◽

Agonist Therapy ◽

Diabetes Patients

Download Full-text

Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy

Postgraduate Medicine ◽

10.1080/00325481.2020.1798127 ◽

2020 ◽

Vol 132 (sup2) ◽

pp. 26-36 ◽

Cited By ~ 2

Author(s):

Eugene E. Wright Jr ◽

Vanita R. Aroda

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Clinical Review ◽

Receptor Agonist ◽

Efficacy And Safety ◽

Agonist Therapy

Download Full-text